Evercore ISI analyst Elizabeth Anderson initiated coverage of Elevance Health (ELV) with an In Line rating and $345 price target Elevance is a diversified managed care company with “resilient” earnings in the current environment, the analyst tells investors in a research note. The firm thinks the company can meet or exceed its 2026 guidance, but sees downside risk to 2027 estimates. There is a “meaningful likelihood” the One Big Beautiful Bill work requirements could lead to “another wave of rate-acuity mismatch” in Medicaid, contends Evercore.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Midday Fly By: Health insurers get ‘positive surprise’ from CMS
- Deutsche sees margin pressure despite ‘positive surprise’ from CMS
- Elevance Health price target raised to $405 from $385 at BofA
- Closing Bell Movers: Health insurers rise on higher Medicare rate hike
- HUM, UNH, CVS: Healthcare Stocks Soar on 2.48% Medicare Rate Increase